Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2022 | The role of next-generation BTK inhibitors in the treatment of CLL

Matthew Davids • 12 Jun 2022
EHA 2022
Chronic Lymphocytic Leukemia Leukemia Acalabrutinib Ibrutinib Pirtobrutinib Venetoclax Zanubrutinib

Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, briefly discusses the role of next-generation Bruton’s tyrosine kinase (BTK) inhibitors, including acalabrutinib, zanubrutinib, and pirtobrutinib, in the treatment of chronic lymphocytic leukemia (CLL). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Matthew Davids

Strategies being explored for the potential management of monoclonal B-cell lymphocytosis 0:47
Strategies being explored for the potential management of monoclonal B-cell lymphocytosis
Matthew Davids • 13 Sep 2025
A tandem CD19/ROR1 CAR-NK to overcome apoptotic resistance in CLL 1:20
A tandem CD19/ROR1 CAR-NK to overcome apoptotic resistance in CLL
Matthew Davids • 13 Sep 2025
MAVRiC trial: mutation-guided time-limited AV after frontline cBTKi + ven in patients with CLL/SLL 1:19
MAVRiC trial: mutation-guided time-limited AV after frontline cBTKi + ven in patients with CLL/SLL
Matthew Davids • 13 Sep 2025
The SOUNDTRACK-E trial: investigating AZD0486 in CLL, MCL, and DLBCL 1:20
The SOUNDTRACK-E trial: investigating AZD0486 in CLL, MCL, and DLBCL
Matthew Davids • 13 Sep 2025

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals